## Drug Summary
Clonidine is an alpha-2 adrenergic receptor agonist primarily indicated for the treatment of hypertension. Its efficacy extends to applications such as severe cancer pain management in combination with opiates, treatment of attention deficit hyperactivity disorder (ADHD), and alleviation of withdrawal symptoms in drug dependence cases. Clonidine achieves its effects by stimulating alpha-2 adrenoceptors leading to lowered blood pressure, sedation, and hyperpolarization of nerves. Administered orally or transdermally with a bioavailability between 55-87%, it peaks in concentration about 1-1.5 hours post-intake. Notably, its metabolism is not entirely clear, though it is partially metabolized in the liver with less than 50% of the drug being transformed into inactive metabolites.

## Drug Targets, Enzymes, Transporters, and Carriers
Clonidine primarily targets alpha-2 adrenergic receptors (ADRA2A, ADRA2B, ADRA2C), linked to its hypotensive and sedative effects, and also binds minimally to alpha-1 receptors (ADRA1A, ADRA1B, ADRA1D) which may contribute to its vascular effects. The drug's metabolism involves several cytochrome P450 enzymes, notably CYP2D6 and CYP3A4, with CYP1A2, CYP1A1, and CYP3A5 also playing roles. Transport-wise, clonidine interacts with solute carrier family members SLC22A3, SLC22A4, and SLC22A5, which could affect its pharmacokinetics. Additionally, it binds to serum albumin (ALB), influencing its distribution within the body.

## Pharmacogenetics
The pharmacogenetic profile of clonidine is influenced mainly by its interaction with metabolic enzymes like CYP2D6 and CYP3A4. Variations in these genes can significantly affect the drug's pharmacokinetics and response. For example, individuals with reduced CYP2D6 activity might experience altered metabolism leading to variations in drug levels and effects. Additionally, genetic variations in alpha-2 adrenergic receptor genes (ADRA2A, ADRA2B, ADRA2C) could theoretically affect the therapeutic responses to clonidine, though specific interactions require further clinical validation. Understanding these genetic interactions helps in tailoring treatments to achieve optimal therapeutic outcomes while avoiding adverse effects.